Lung cancer drug poised for global approval, says MWC investigator
11 December 2017
Dacomitinib, an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed in collaboration with Pfizer by researchers led by MWC Associate Investigator Dr. Jeff Smaill, has shown significant efficacy in the treatment of patients with non-small-...
Dr Aniruddha Chatterjee awarded Rutherford Discovery Fellowship
13 October 2017
MWC Affiliate Investigator Dr Aniruddha Chatterjee of the University of Otago is one of only ten recipients across the country to be awarded a 2017 Rutherford Discovery Fellowship.
Newly funded research highlights MWC collaborations
7 November 2016
Professor Gavin Painter from Victoria University’s Ferrier Research Institute has been awarded funding in the Ministry of Business, Innovation and Employment’s 2016 Endeavour Fund science investment round.
Prestigious award for cancer researcher
11 September 2016
Cancer biologist Professor Antony Braithwaite has received the New Zealand Association of Scientists (NZAS) Shorland Medal in recognition of his work on the tumour suppressor protein p53 and other cancer associated genes.
MWC investigators awarded 14 grants in national health research funding
15 June 2016
Investigators with the Maurice Wilkins Centre for Molecular Biodiscovery have been awarded a total of 14 project grants in the annual Health Research Council of New Zealand (HRC) funding round.
MWC investigators discuss cancer drugs on Radio New Zealand
24 February 2016
Maurice Wilkins Centre (MWC) investigators Professor Rod Dunbar, Professor Bill Wilson, and Dr Francis Hunter discuss cancer immunotherapy drugs on Radio New Zealand.
New collaboration between New Zealand and China in medical science
16 November 2015
A joint centre for medical research established between China and New Zealand is the first of its kind and will focus on leading-edge medical science to seek new treatments for diseases such as cancer.
Avalia Immunotherapies to advance immunotherapy technology
21 May 2015
An immunotherapy technology for treating cancer and other diseases, jointly developed by Victoria University of Wellington’s Ferrier Research Institute and the Malaghan Institute of Medical Research, has been patented and will be the initial focus of a newly-formed company, ...